Life Sciences

Capitol Hill is awash in proposals to stem allegedly out-of-control drug prices, but in their zealousness to rein in drug prices, policymakers risk imperiling drug innovation to the detriment of patients and the economy. The better way to produce more medical cures at lower cost over the long haul will be to double down on innovation, not deter it.
Life Sciences
Check a box to narrow search for individual content items that cover numerous issues.
November 22, 2021
Capitol Hill is awash in proposals to stem allegedly out-of-control drug prices, but in their zealousness to rein in drug prices, policymakers risk imperiling drug innovation to the detriment of patients and the economy. The better way to produce more medical cures at lower cost over the long haul will be to double down on innovation, not deter it.
November 22, 2021
America has lost 70 percent of its semiconductor manufacturing capacity over the last three decades. That serves as a harsh lesson for policymakers: Failing to maintain a supportive policy environment could set up other high-tech industries to falter, too.
November 15, 2021
The United States is the leader in life sciences innovation, but that has not always been the case. As global competition intensifies, it needs to continue spurring investment in R&D to stay on top. Rob and Jackie sat down with Stephen Ezell, vice president of global innovation policy at ITIF, to discuss the history of U.S. life sciences innovation and break down R&D costs versus the market prices of innovative biopharmaceuticals.
October 18, 2021
When factoring in the high value of positive externalities created by new drugs, consumer prices become a small price to pay for the wealth of private and public benefits that biopharmaceutical innovations create.
August 16, 2021
This growth comes with real-world improvements to patient outcomes. The decade from 2010 through 2019 saw a 60 percent increase in new drug approvals compared to the previous decade.
June 16, 2021
ITIF hosted an in-depth discussion with members of the Biden Administration about the report, implications for policy, and potential next steps.
May 20, 2021
In her sensationally titled report, “Killer Profits: How Big Pharma Takeovers Destroy Innovation and Harm Patients,” the deputy chair of the Congressional Progressive Caucus issued an ideologically inspired jeremiad grounded in assertions that are easily refuted with data.
May 10, 2021
Those who really want to solve the problem should abandon ill-advised proposals like patent waivers and focus instead on cooperative solutions to overcoming supply-chain constraints. The sooner that happens, the sooner we can all breathe freely again.
April 29, 2021
ITIF hosted an expert panel discussion about the report and the vital role IP has played throughout the pandemic.
April 29, 2021
From vaccines and therapeutics to delivery robots, intellectual property has played an indispensable role in facilitating development of a range of inventive products that have helped address health care, work, and social challenges brought on by the pandemic.

Pages